Logo do repositório
 
Publicação

Portuguese recommendations for the management of transthyretin amyloid cardiomyopathy (Part 1 of 2): screening, diagnosis and treatment. Developed by the task force on the management of transthyretin amyloid cardiomyopathy of the working group on myocardial and pericardial diseases of the portuguese society of cardiology

datacite.subject.sdg03:Saúde de Qualidade
datacite.subject.sdg09:Indústria, Inovação e Infraestruturas
datacite.subject.sdg10:Reduzir as Desigualdades
dc.contributor.authorMarques, Nuno
dc.contributor.authorRosa, Sílvia Aguiar
dc.contributor.authorCordeiro, Filipa
dc.contributor.authorFernandes, Raquel Menezes
dc.contributor.authorFerreira, Catarina
dc.contributor.authorBento, Dina
dc.contributor.authorBrito, Dulce
dc.contributor.authorCardim, Nuno
dc.contributor.authorLopes, Luís
dc.contributor.authorAzevedo, Olga
dc.date.accessioned2026-04-30T09:29:26Z
dc.date.available2026-04-30T09:29:26Z
dc.date.issued2025-02
dc.description.abstractThe Portuguese recommendations for the management of transthyretin amyloid cardiomyopathy (ATTR-CM) evaluate and summarize the available evidence and provide evidence-based recommendations on the best management of patients with ATTR-CM. These recommendations represent the official position of the Working Group on Myocardial and Pericardial Diseases (WGMPD) of the Portuguese Society of Cardiology. The Portuguese WGMPD selected the members of this Task Force as expert professionals involved in the care of patients with this disease. The Task Force performed a critical evaluation of the available evidence on the diagnostic procedures and therapeutic options for ATTR-CM, including an assessment of risk-benefit ratios. The strength of every recommendation and its level of evidence were weighed and scored according to predefined scales, usually those used by the European Society of Cardiology (ESC) in their guidelines, as outlined below in Tables 1 and 2. This Task Force followed voting procedures, and all approved recommendations were subject to a vote and achieved at least 75% agreement among voting members. The experts of the writing panels provided declaration of interest forms for all relationships that might be perceived as actual or potential sources of conflicts of interest. These recommendations were developed without any financial support or involvement of the healthcare industry. The Portuguese WGMPD supervised and coordinated the preparation of these recommendations and was responsible for the approval process. After appropriate revisions, the recommendations were signed off by all the experts involved in the Task Force. The WGMPD submitted the final document for publication in the official journal of the Portuguese Society of Cardiology, Revista Portuguesa de Cardiologia (Portuguese Journal of Cardiology). The recommendations were developed after careful consideration of the scientific knowledge and evidence available at the time of writing. Tables of recommendations are provided in this document along with the corresponding class of recommendation and level of evidence for each statement. Specific areas on which there are uncertainties concerning the existing evidence for the recommendation were also identified. The Task Force members carried out systematic reviews of the literature on these topics, which will be provided in separate publications. These recommendations do not override the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each individual patient’s health condition.eng
dc.identifier.doi10.1016/j.repc.2024.11.009
dc.identifier.issn0870-2551
dc.identifier.urihttp://hdl.handle.net/10400.1/28821
dc.language.isoeng
dc.peerreviewedyes
dc.publisherSociedade Portuguesa de Cardiologia
dc.relation.ispartofRevista Portuguesa de Cardiologia
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAmyloidosis
dc.subjectCardiac amyloidosis
dc.subjectTransthyretin amyloid cardiomyopathy
dc.subjectTransthyretin
dc.subjectDiagnosis
dc.subjectScreening
dc.subjectTreatment
dc.subjectRecommendations
dc.titlePortuguese recommendations for the management of transthyretin amyloid cardiomyopathy (Part 1 of 2): screening, diagnosis and treatment. Developed by the task force on the management of transthyretin amyloid cardiomyopathy of the working group on myocardial and pericardial diseases of the portuguese society of cardiologyeng
dc.title.alternativeRecomendações portuguesas da amiloidose cardíaca ATTR (parte 1 de 2): rastreio, diagnóstico e tratamento. Desenvolvidas pelo grupo de trabalho para as recomendações da ATTR-CM do grupo de estudos das doençãs do miocárdio e do pericárdio da sociedade portuguesa de cardiologiapor
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage48
oaire.citation.startPage7
oaire.citation.titleRevista Portuguesa de Cardiologia
oaire.citation.volume44
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameMarques
person.givenNameNuno
person.identifier.orcid0000-0003-0275-2807
relation.isAuthorOfPublication1b66ba1f-d295-4211-b41e-c0f0b622eea0
relation.isAuthorOfPublication.latestForDiscovery1b66ba1f-d295-4211-b41e-c0f0b622eea0

Ficheiros

Principais
A mostrar 1 - 1 de 1
A carregar...
Miniatura
Nome:
1-s2.0-S087025512500023X-main.pdf
Tamanho:
5.56 MB
Formato:
Adobe Portable Document Format
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
3.46 KB
Formato:
Item-specific license agreed upon to submission
Descrição: